A journey toward Pharmaceutical Innovation

Founded in 1997 in York, UK, Xceleron provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. 

Xceleron pioneered human microtracer techniques as a way to accelerate drug development and has unmatched robust processes and knowledge of experimental design. There are currently 6 drugs on the market that have used Xceleron AMS data in filing, and another 3 in late stages of development. In 2008, the company opened its US facility in Maryland.

Xceleron's experience is especially valuable today because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.

Our services can be tailored specifically for each project. We ensure that all aspects of an early human trial are managed quickly and cost-effectively.

Xceleron has been providing insight into early human drug development for more than 10 years and has conducted more GLP and GCP studies than any other CRO of its type.